Precipio Inc Dossier
Qualitative Analysis
Business overview
Precipio, Inc. (NASDAQ: PRPO) is a healthcare biotechnology and specialty cancer diagnostics company focused on addressing the pervasive problem of cancer misdiagnosis, with an initial concentration on hematologic malignancies. Headquartered in New Haven, Connecticut, the company operates an integrated business model combining a CLIA-certified clinical pathology laboratory with a proprietary diagnostics product division. This dual-division structure consists of the Pathology Services Division, which delivers specialized cancer diagnostic testing services from facilities in New Haven, CT and Omaha, Nebraska, and the Products Division, which develops and commercializes proprietary assays and reagents for the global laboratory community. Key proprietary product offerings include HemeScreen, a suite of robust genetic diagnostic panels, and IV-Cell, a proprietary cell culture media enabling simultaneous culturing of four hematopoietic cell lineages. Precipio leverages national distribution agreements with major partners such as McKesson, Fisher Healthcare, Cardinal Health, and Medline to reach physician-owned laboratories, hospital academic centers, and reference labs without maintaining a costly direct sales organization.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the commercial team for the Products Division by hiring a Chief Commercial Officer and two full-time business development officers in January 2026 to drive direct sales and strengthen relationships with national distributors.
Expected impact: Aims to accelerate the adoption of HemeScreen and Bloodhound molecular platforms, shifting the company's revenue mix from a 90/10 pathology-to-product split toward a more balanced 50/50 mix over the next 3 to 5 years.
Repaying outstanding financial obligations and clearing balance sheet overhangs to improve liquidity and financial independence.
Expected impact: Eliminated financial overhangs, reduced long-term debt, and improved the company's overall capital structure.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
These partnerships form the backbone of Precipio's go-to-market strategy, allowing the company to reach physician-owned laboratories, hospital and academic centers, and reference labs nationwide without the overhead of a massive direct sales force.
Terms: Not disclosed
Collaborated on a joint academic study demonstrating the novel clinical value of Precipio's Bloodhound BCR-ABL1 assay, enhancing the product's scientific credibility and market adoption.
Terms: Not disclosed